P. Heering
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
P. Heering has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
B Grabensee
8 shared publicationsB. Grabensee
8 shared publications- Katrin Ivens
Klinik für Nephrologie am Universitätsklinikum der Heinrich-Heine-Universität Düsseldorf
4 shared publications A Scheid
2 shared publicationsB. Kutkuhn
Abteilung für Nephrologie, Universität Düsseldorf
2 shared publicationsD Bach
2 shared publications
Latest Publications
- 1 April 2004
- Published by Dustri-Verlag Dr. Karl Feistle in Nieren- und Hochdruckkrankheiten
- Vol. 33 (4) , 167-176
Einfluß genetischer Polymorphismen des Renin-Angiotensin-Systems auf die membranöse Glomerulonephritis
- 1 April 2004
- Published by Dustri-Verlag Dr. Karl Feistle in Nieren- und Hochdruckkrankheiten
- Vol. 33 (4) , 167-176
Einfluß genetischer Polymorphismen des Renin-Angiotensin-Systems auf die membranöse Glomerulonephritis
- 5 June 2003
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 26 (2) , 128-134
Cytokine Removal in Septic Patients with Continuous Venovenous Hemofiltration
Despite the progress that has been made in intensive care medicine, multiple organ failure is still associated with high mortality. Apart from the prevention of infectious complications, numerous efforts are being made to improve the treatment of sepsis through adequate antibiotic therapy, the development of new respirator therapies, better control of the hemodynamic situation, and adequate renal replacement therapy. Some authors advocate continuous renal replacement therapy not only for acute renal failure but also for the elimination of inflammatory molecules such as cytokines. Continuous renal replacement therapy improves the cardiovascular hemodynamics in patients with multiple organ failure. Therapeutic options such as volume control, clearance of uremic toxins, correction of acid base disturbances and temperature control are improved. Suitable renal replacement therapy improves not only cardiovascular hemodynamics but also patient survival. In current practice, continuous renal replacement therapy is not used to eliminate mediators such as cytokines. In patients with multiple organ failure and compromised cardiovascular hemodynamics, renal replacement therapy should be carried out as early as possible. In the following review, experimental and clinical findings concerning mediator elimination by continuous and intermittent renal replacement therapy are summarized.
- 5 June 2003
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 26 (2) , 128-134
Cytokine Removal in Septic Patients with Continuous Venovenous Hemofiltration
Despite the progress that has been made in intensive care medicine, multiple organ failure is still associated with high mortality. Apart from the prevention of infectious complications, numerous efforts are being made to improve the treatment of sepsis through adequate antibiotic therapy, the development of new respirator therapies, better control of the hemodynamic situation, and adequate renal replacement therapy. Some authors advocate continuous renal replacement therapy not only for acute renal failure but also for the elimination of inflammatory molecules such as cytokines. Continuous renal replacement therapy improves the cardiovascular hemodynamics in patients with multiple organ failure. Therapeutic options such as volume control, clearance of uremic toxins, correction of acid base disturbances and temperature control are improved. Suitable renal replacement therapy improves not only cardiovascular hemodynamics but also patient survival. In current practice, continuous renal replacement therapy is not used to eliminate mediators such as cytokines. In patients with multiple organ failure and compromised cardiovascular hemodynamics, renal replacement therapy should be carried out as early as possible. In the following review, experimental and clinical findings concerning mediator elimination by continuous and intermittent renal replacement therapy are summarized.
- 24 August 2000
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 125 (34/35) , 997-1002
Therapieoptionen bei systemischer AL-Amyloidose mit Nierenbeteiligung
Hintergrund und Fragestellung: Die Prognose der systemischen AL-Amyloidose ist trotz gesicherter Effekte einer Chemotherapie mit Melphalan und Prednison sehr ungünstig. Die beschriebenen Behandlungsergebnisse bei Patienten mit schwerer Nierenamyloidose sind uneinheitlich. Es ist unklar, ob durch eine konventionelle Melphalantherapie klinische Erfolge zu erzielen sind. Patienten und Methodik: Wir berichten über die Therapieergebnisse bei 22 Patienten mit vordergründiger Nierenbeteiligung bei systemischer AL-Amyloidose ohne fortgeschrittenes Myelom. Das mittlere Alter der acht Frauen und 14 Männer betrug 60 Jahre. Zum Zeitpunkt der histologischen Sicherung der Amyloidose war bei allen Patienten eine Proteinurie meist mit nephrotischem Syndrom oder eine Niereninsuffizienz nachweisbar. Ergebnisse: Zehn Patienten wurden mit einer konventionellen Melphalantherapie und Steroiden behandelt. In keinem Fall sahen wir eine eindeutige Verbesserung der Symptomatik, die Patienten verstarben im Mittel 12 Monate nach Diagnosestellung. Drei Patienten erhielten eine Hochdosis-Melphalantherapie mit autologer Stammzelltransplantation. Ein Patient verstarb an einer Komplikation, zwei Patienten leben bei eindeutiger klinischer Besserung und anhaltender Remission der Grunderkrankung 12 bzw. 18 Monate nach der Stammzelltransplantation. Weitere neun Patienten wurden symptomatisch-supportiv behandelt, vier von ihnen leben im Mittel 30 Monate nach Diagnosestellung. Folgerungen: Trotz deutlicher therapieassoziierter Risiken bot allein die Hochdosis-Melphalantherapie eine realistische Chance auf eine Remission der Grunderkrankung und eine Verbesserung bestehender klinischer Symptome. Bei Patienten mit schwerer Nierenbeteiligung, die auf Grund der Co-Morbidität oder des Alters in dieser Form nicht behandelt werden können, müssen potenzieller Nutzen und Risiken der konventionellen Melphalantherapie abgewogen werden. Da eine Verbesserung der klinischen Symptome bei dieser Therapie unwahrscheinlich und eine Prognoseverbesserung nicht gesichert ist, sehen wir in diesen Fällen keine absolute Indikation zur Chemotherapie. Background and objective: Despite significant efficacy of melphalan and prednisone in the therapy of systemic AL(light chain amyloid)amyloidosis the prognosis of the disease is poor. In patients with severe renal manifestation the reported results of low-dose melphalan therapy are inconclusive with respect to relief of clinical symptoms and overall prognosis. Patients and methods: We report our results of therapy in a group of 22 patients (8 women, 14 men, mean age 60 years) with renal involvement as the main manifestation of systemic AL-amyloidosis without overt myeloma. Results: Ten patients were treated with low doses of melphalan and prednisone. No significant clinical improvement was observed in any case: the patients died an average of 12 months after diagnosis of the disease. Three patients were treated with high doses of melphalan followed by autologous stem cell transplantation. One patient died due to septicaemia after high-dose chemotherapy. Two of the patients experienced significant remission and live virtually free of clinical symptoms 12 and 18 months after therapy. Nine patients were treated only symptomatically: four of them were alive an average of 30 months after diagnosis of systemic AL-amyloidosis. Conclusion: Only high-dose melphalan therapy offered a realistic chance of amelioration of clinical symptoms in our group of patients, although therapy-associated risks seem to be high. In patients with severe renal amyloidosis, who are not considered for high-dose therapy, particularly careful consideration of potential benefits and possible risks of conventional melphalan therapy is necessary, because the results of this approach are in doubt.
- 24 August 2000
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 125 (34/35) , 997-1002
Therapieoptionen bei systemischer AL-Amyloidose mit Nierenbeteiligung
Hintergrund und Fragestellung: Die Prognose der systemischen AL-Amyloidose ist trotz gesicherter Effekte einer Chemotherapie mit Melphalan und Prednison sehr ungünstig. Die beschriebenen Behandlungsergebnisse bei Patienten mit schwerer Nierenamyloidose sind uneinheitlich. Es ist unklar, ob durch eine konventionelle Melphalantherapie klinische Erfolge zu erzielen sind. Patienten und Methodik: Wir berichten über die Therapieergebnisse bei 22 Patienten mit vordergründiger Nierenbeteiligung bei systemischer AL-Amyloidose ohne fortgeschrittenes Myelom. Das mittlere Alter der acht Frauen und 14 Männer betrug 60 Jahre. Zum Zeitpunkt der histologischen Sicherung der Amyloidose war bei allen Patienten eine Proteinurie meist mit nephrotischem Syndrom oder eine Niereninsuffizienz nachweisbar. Ergebnisse: Zehn Patienten wurden mit einer konventionellen Melphalantherapie und Steroiden behandelt. In keinem Fall sahen wir eine eindeutige Verbesserung der Symptomatik, die Patienten verstarben im Mittel 12 Monate nach Diagnosestellung. Drei Patienten erhielten eine Hochdosis-Melphalantherapie mit autologer Stammzelltransplantation. Ein Patient verstarb an einer Komplikation, zwei Patienten leben bei eindeutiger klinischer Besserung und anhaltender Remission der Grunderkrankung 12 bzw. 18 Monate nach der Stammzelltransplantation. Weitere neun Patienten wurden symptomatisch-supportiv behandelt, vier von ihnen leben im Mittel 30 Monate nach Diagnosestellung. Folgerungen: Trotz deutlicher therapieassoziierter Risiken bot allein die Hochdosis-Melphalantherapie eine realistische Chance auf eine Remission der Grunderkrankung und eine Verbesserung bestehender klinischer Symptome. Bei Patienten mit schwerer Nierenbeteiligung, die auf Grund der Co-Morbidität oder des Alters in dieser Form nicht behandelt werden können, müssen potenzieller Nutzen und Risiken der konventionellen Melphalantherapie abgewogen werden. Da eine Verbesserung der klinischen Symptome bei dieser Therapie unwahrscheinlich und eine Prognoseverbesserung nicht gesichert ist, sehen wir in diesen Fällen keine absolute Indikation zur Chemotherapie. Background and objective: Despite significant efficacy of melphalan and prednisone in the therapy of systemic AL(light chain amyloid)amyloidosis the prognosis of the disease is poor. In patients with severe renal manifestation the reported results of low-dose melphalan therapy are inconclusive with respect to relief of clinical symptoms and overall prognosis. Patients and methods: We report our results of therapy in a group of 22 patients (8 women, 14 men, mean age 60 years) with renal involvement as the main manifestation of systemic AL-amyloidosis without overt myeloma. Results: Ten patients were treated with low doses of melphalan and prednisone. No significant clinical improvement was observed in any case: the patients died an average of 12 months after diagnosis of the disease. Three patients were treated with high doses of melphalan followed by autologous stem cell transplantation. One patient died due to septicaemia after high-dose chemotherapy. Two of the patients experienced significant remission and live virtually free of clinical symptoms 12 and 18 months after therapy. Nine patients were treated only symptomatically: four of them were alive an average of 30 months after diagnosis of systemic AL-amyloidosis. Conclusion: Only high-dose melphalan therapy offered a realistic chance of amelioration of clinical symptoms in our group of patients, although therapy-associated risks seem to be high. In patients with severe renal amyloidosis, who are not considered for high-dose therapy, particularly careful consideration of potential benefits and possible risks of conventional melphalan therapy is necessary, because the results of this approach are in doubt.
- 1 November 1999
- Vol. 52 (5) , 285-92
The "point of no return" and the rate of progression in the natural history of IgA nephritis.
Based on the observation of 7 patients with chronic IgA nephritis and on a course to end-stage renal failure after several years, D'Amico et al. [1993] reported on a "point of no return" at 2.5 to 3 mg/dl serum creatinine. After exceeding this limit all 7 patients exhibited an irreversible progressive renal failure. Therefore, 115 patients with IgA nephritis from the "German Glomerulonephritis Therapy Study" were examined in order to look for the existence of such a "point of no return". Three different courses could be distinguished: a stable chronic course with constantly normal or only minor elevated serum creatinine lasting for years (91 patients), a progressive course with continuously increasing serum creatinine (22 patients), and a rare (only 2 patients) early acute course with a short-term increase of serum creatinine followed by a rapid return to the normal range. After exceeding 3 mg/dl serum creatinine no remissions were observed in the progressive cases. Sixteen patients showed a rapid, continuously progressive course until end-stage renal failure with exactly the same progression as the 7 patients of D'Amico et al. Six patients of the 22 progressors were not observed long enough. The serum creatinine level doubled on average from 3 to 6 mg/dl within 10 months. Our study confirmed the existence of a "point of no return" at 3 mg/dl (265 micromol/l) during the natural course of chronic IgA nephritis.
- 1 November 1999
- Vol. 52 (5) , 285-92
The "point of no return" and the rate of progression in the natural history of IgA nephritis.
Based on the observation of 7 patients with chronic IgA nephritis and on a course to end-stage renal failure after several years, D'Amico et al. [1993] reported on a "point of no return" at 2.5 to 3 mg/dl serum creatinine. After exceeding this limit all 7 patients exhibited an irreversible progressive renal failure. Therefore, 115 patients with IgA nephritis from the "German Glomerulonephritis Therapy Study" were examined in order to look for the existence of such a "point of no return". Three different courses could be distinguished: a stable chronic course with constantly normal or only minor elevated serum creatinine lasting for years (91 patients), a progressive course with continuously increasing serum creatinine (22 patients), and a rare (only 2 patients) early acute course with a short-term increase of serum creatinine followed by a rapid return to the normal range. After exceeding 3 mg/dl serum creatinine no remissions were observed in the progressive cases. Sixteen patients showed a rapid, continuously progressive course until end-stage renal failure with exactly the same progression as the 7 patients of D'Amico et al. Six patients of the 22 progressors were not observed long enough. The serum creatinine level doubled on average from 3 to 6 mg/dl within 10 months. Our study confirmed the existence of a "point of no return" at 3 mg/dl (265 micromol/l) during the natural course of chronic IgA nephritis.
- 1 March 1997
- Published by Springer Nature in International Urology and Nephrology
- Vol. 29 (2) , 245-250
Erythropoietin in patients with acute renal failure and continuous veno-venous haemofiltration
Erythropoietin (Epo) is a glycoprotein hormone produced in the kidney in response to hypoxia or anaemia. In acute renal failure (ARF) anaemia also occurs and current opinion is that Epo production is depressed with inappropriately low plasma levels throughout the uraemic phase. Our study was designed to determine the excretion of Epo in patients with ARF. Fifty-nine ventilated patients were studied, 39 with ARF and continuous veno-venous haemofiltration therapy (group 1) and 13 patients with normal renal function who served as a control group (group 2). All patients with ARF were anaemic and needed a mean transfusion of 0.6 units/day. Values for vitamin B12, folic acid, serum iron and ferritin were normal. While patients with normal renal function had Epo values within the normal range, patients with ARF had significantly higher values at the onset of haemofiltration therapy. Mean Epo (mean±SEM) values on days 0–2 were 92.6±11.7 mU/ml in group 1 and 16.5±6.4 mU/ml in group 2 (p<0.0002). Epo levels declined in group 1 to 49±10.5 mU/ml on days 9 and 10 compared to 23±9.1 mU/ml in group 2 (ns). These values were maintained until the end of the observation period. No differences were seen between oliguric and non-oliguric patients. Our data show that patients with ARF have increased Epo levels at the beginning of the disease with a strong tendency to decrease, suggesting that there might be inadequate Epo levels during the course of acute renal failure.
- 1 March 1997
- Published by Springer Nature in International Urology and Nephrology
- Vol. 29 (2) , 245-250
Erythropoietin in patients with acute renal failure and continuous veno-venous haemofiltration
Erythropoietin (Epo) is a glycoprotein hormone produced in the kidney in response to hypoxia or anaemia. In acute renal failure (ARF) anaemia also occurs and current opinion is that Epo production is depressed with inappropriately low plasma levels throughout the uraemic phase. Our study was designed to determine the excretion of Epo in patients with ARF. Fifty-nine ventilated patients were studied, 39 with ARF and continuous veno-venous haemofiltration therapy (group 1) and 13 patients with normal renal function who served as a control group (group 2). All patients with ARF were anaemic and needed a mean transfusion of 0.6 units/day. Values for vitamin B12, folic acid, serum iron and ferritin were normal. While patients with normal renal function had Epo values within the normal range, patients with ARF had significantly higher values at the onset of haemofiltration therapy. Mean Epo (mean±SEM) values on days 0–2 were 92.6±11.7 mU/ml in group 1 and 16.5±6.4 mU/ml in group 2 (p<0.0002). Epo levels declined in group 1 to 49±10.5 mU/ml on days 9 and 10 compared to 23±9.1 mU/ml in group 2 (ns). These values were maintained until the end of the observation period. No differences were seen between oliguric and non-oliguric patients. Our data show that patients with ARF have increased Epo levels at the beginning of the disease with a strong tendency to decrease, suggesting that there might be inadequate Epo levels during the course of acute renal failure.
- 1 January 1996
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 121 (24) , 788-792
Kardiochirurgische Therapie der koronaren Herzkrankheit bei terminaler Niereninsuffizienz
Grundproblematik und Fragestellung: Retrospektiv wurden die Ergebnisse nach aortokoronarer Bypass-Operation bei Dialysepatienten ausgewertet, um Komplikationen und Langzeitergebnisse zu erfassen. Patienten und Methodik: Zwischen 1982 und 1992 wurden 65 Dialysepatienten (54 Männer, elf Frauen) mit koronarer Herzkrankheit (KHK) einer aortokoronaren Bypass-Operation zugeführt. Das Durchschnittsalter betrug 56,9 ± 8,1 Jahre, die mittlere Dialysedauer 41,1 ± 45,0 (1-215) Monate. Intraoperativ wurde bei allen Patienten im Nebenschluß zur Herz-Lungen-Maschine eine Hämofiltration durchgeführt. Ergebnisse: Die Auswertung der Koronarangiographien zeigte bei 40 Patienten (62 %) eine koronare 3-Gefäß-Krankheit. Die Anzahl der Gefäßbrücken betrug durchschnittlich 2,8 pro Patient. Die perioperative Letalität lag bei 4,6 %. 6 Monate nach der Bypass-Operation waren 95 % der Überlebenden beschwerdefrei. Die Langzeitüberlebensrate betrug 71,0 % nach 3 Jahren und 55 % nach 5 Jahren. Folgerung: Die aortokoronare Bypass-Operation bei Dialysepatienten mit koronarer Herzkrankheit ist mit kalkulierbarem Risiko durchführbar und führt zu einer deutlichen Verbesserung der Beschwerden. Objective: To determine retrospectively the complications and long-term results of aortocoronary bypass grafting in patients with end-stage renal disease. Patients and methods: 65 patients with coronary heart disease (CHD) and on dialysis (54 men, 11 women; average age 56.9 ± 8.1 years) underwent aortocoronary bypass grafting between 1982 and 1992. Mean duration of dialysis (haemo- or peritoneal) was 41.1 ± 45.0 (1-215) months. All patients had had haemofiltration treatment in conjunction with the bypass operation. Results: Coronary angiography demonstrated triple-vessel disease in 40 patients (62 %). Average number of bypasses was 2.8 per patient. Perioperative death rate was 4.6 %. 95 % of survivors were free of symptoms 6 months postoperatively. Long-term survival rate was 71 % after 3 years and 55 % after 5 years. Conclusion: Aortocoronary bypass grafting for CHD in patients with end-stage renal disease can be performed with a low perioperative mortality rate and significantly improves symptoms.
- 1 January 1996
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 121 (24) , 788-792
Kardiochirurgische Therapie der koronaren Herzkrankheit bei terminaler Niereninsuffizienz
Grundproblematik und Fragestellung: Retrospektiv wurden die Ergebnisse nach aortokoronarer Bypass-Operation bei Dialysepatienten ausgewertet, um Komplikationen und Langzeitergebnisse zu erfassen. Patienten und Methodik: Zwischen 1982 und 1992 wurden 65 Dialysepatienten (54 Männer, elf Frauen) mit koronarer Herzkrankheit (KHK) einer aortokoronaren Bypass-Operation zugeführt. Das Durchschnittsalter betrug 56,9 ± 8,1 Jahre, die mittlere Dialysedauer 41,1 ± 45,0 (1-215) Monate. Intraoperativ wurde bei allen Patienten im Nebenschluß zur Herz-Lungen-Maschine eine Hämofiltration durchgeführt. Ergebnisse: Die Auswertung der Koronarangiographien zeigte bei 40 Patienten (62 %) eine koronare 3-Gefäß-Krankheit. Die Anzahl der Gefäßbrücken betrug durchschnittlich 2,8 pro Patient. Die perioperative Letalität lag bei 4,6 %. 6 Monate nach der Bypass-Operation waren 95 % der Überlebenden beschwerdefrei. Die Langzeitüberlebensrate betrug 71,0 % nach 3 Jahren und 55 % nach 5 Jahren. Folgerung: Die aortokoronare Bypass-Operation bei Dialysepatienten mit koronarer Herzkrankheit ist mit kalkulierbarem Risiko durchführbar und führt zu einer deutlichen Verbesserung der Beschwerden. Objective: To determine retrospectively the complications and long-term results of aortocoronary bypass grafting in patients with end-stage renal disease. Patients and methods: 65 patients with coronary heart disease (CHD) and on dialysis (54 men, 11 women; average age 56.9 ± 8.1 years) underwent aortocoronary bypass grafting between 1982 and 1992. Mean duration of dialysis (haemo- or peritoneal) was 41.1 ± 45.0 (1-215) months. All patients had had haemofiltration treatment in conjunction with the bypass operation. Results: Coronary angiography demonstrated triple-vessel disease in 40 patients (62 %). Average number of bypasses was 2.8 per patient. Perioperative death rate was 4.6 %. 95 % of survivors were free of symptoms 6 months postoperatively. Long-term survival rate was 71 % after 3 years and 55 % after 5 years. Conclusion: Aortocoronary bypass grafting for CHD in patients with end-stage renal disease can be performed with a low perioperative mortality rate and significantly improves symptoms.
- 1 October 1994
- Vol. 26 (5) , 2656-7
Malignancy under immunosuppressive therapy including cyclosporine.
- 1 October 1994
- Vol. 26 (5) , 2656-7
Malignancy under immunosuppressive therapy including cyclosporine.
- 1 October 1994
- Vol. 26 (5) , 2530-2
Reduction of immunosuppressive therapy after renal transplantation: a randomized study.
- 1 October 1994
- Vol. 26 (5) , 2530-2
Reduction of immunosuppressive therapy after renal transplantation: a randomized study.
- 1 December 1993
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 71 (12) , 1010-1015
Nephrotoxicity of cyclosporine in humans: effect of cyclosporine on glomerular filtration and proximal tubular reabsorption
Summary The chronic nephrotoxic effects of cyclosporine (CsA) include proximal tubular atrophy and vacuolization. This study investigated the effect of CsA on renal hemodynamics and segmental electrolyte transport in CsA-treated patients. The clearance of inulin (CIn) and PAH para-amino-hippuric acid (CPAH) was determined; proximal tubular function was studied using a lithium clearance method and calculating tubular phosphate reabsorption per milliliter of glomerular filtrate (TP/CIn). Twenty patients without renal disease were investigated: ten treated with CsA because of nonrenal grafting (group 1) and ten healthy volunteers (group 2). The results obtained were compared with those from 20 renal allograft recipients, of whom ten were treated with CsA and methylprednisolone (group 3) and ten with azathioprine and methylprednisolone (group 4). CIn and CPAH were significantly impaired in patients treated with CsA. No significant impairment of lithium clearance as induced by CsA was observed. The fractional excretion of lithium was slightly increased in patients treated with CsA compared to their respective controls. TP/CIn was lower in graft recipients compared to controls; no impairment of phosphate reabsorption as induced by CsA was found. The fractional tubular excretion of lithium was slightly increased compared to controls, rising evidence that proximal tubular reabsorption of lithium was decreased. Tubular reabsorption of phosphate was not impaired. The decrease in glomerular filtration and renal perfusion during chronic treatment with CsA was accompanied by a reduced proximal reabsorptive capacity, as was shown by lithium clearance. Our data do not support the hypothesis that functional parameters of the proximal tubular system can be used as indicators of CsA-induced nephrotoxicity.
- 1 December 1993
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 71 (12) , 1010-1015
Nephrotoxicity of cyclosporine in humans: effect of cyclosporine on glomerular filtration and proximal tubular reabsorption
Summary The chronic nephrotoxic effects of cyclosporine (CsA) include proximal tubular atrophy and vacuolization. This study investigated the effect of CsA on renal hemodynamics and segmental electrolyte transport in CsA-treated patients. The clearance of inulin (CIn) and PAH para-amino-hippuric acid (CPAH) was determined; proximal tubular function was studied using a lithium clearance method and calculating tubular phosphate reabsorption per milliliter of glomerular filtrate (TP/CIn). Twenty patients without renal disease were investigated: ten treated with CsA because of nonrenal grafting (group 1) and ten healthy volunteers (group 2). The results obtained were compared with those from 20 renal allograft recipients, of whom ten were treated with CsA and methylprednisolone (group 3) and ten with azathioprine and methylprednisolone (group 4). CIn and CPAH were significantly impaired in patients treated with CsA. No significant impairment of lithium clearance as induced by CsA was observed. The fractional excretion of lithium was slightly increased in patients treated with CsA compared to their respective controls. TP/CIn was lower in graft recipients compared to controls; no impairment of phosphate reabsorption as induced by CsA was found. The fractional tubular excretion of lithium was slightly increased compared to controls, rising evidence that proximal tubular reabsorption of lithium was decreased. Tubular reabsorption of phosphate was not impaired. The decrease in glomerular filtration and renal perfusion during chronic treatment with CsA was accompanied by a reduced proximal reabsorptive capacity, as was shown by lithium clearance. Our data do not support the hypothesis that functional parameters of the proximal tubular system can be used as indicators of CsA-induced nephrotoxicity.
- 1 December 1990
- Vol. 31 (12) , W125-133
[Continuing education. Hematuria].